These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25303382)

  • 1. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
    Moss AC
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1249. PubMed ID: 25303382
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1044-55. PubMed ID: 25185992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response.
    Sutharshan K; Gearry RB
    J Crohns Colitis; 2013 Aug; 7(7):e277-8. PubMed ID: 23434316
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease.
    Van Assche G; Baert F; Vermeire S
    Aliment Pharmacol Ther; 2012 Apr; 35(7):848; discussion 849. PubMed ID: 22404407
    [No Abstract]   [Full Text] [Related]  

  • 5. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients.
    Bultman E; de Haar C; van Liere-Baron A; Verhoog H; West RL; Kuipers EJ; Zelinkova Z; van der Woude CJ
    Aliment Pharmacol Ther; 2012 Feb; 35(3):335-41. PubMed ID: 22191671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricular tachyarrhythmia after adalimumab therapy in a patient with Crohn's disease.
    Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Linke K
    Acta Gastroenterol Belg; 2013 Mar; 76(1):74-5. PubMed ID: 23650791
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
    Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
    Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
    Billioud V; Sandborn WJ; Peyrin-Biroulet L
    Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
    Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B
    Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal Crohn's disease treated successfully with adalimumab.
    Kwan LY; Conklin JL; Papadakis KA
    Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
    [No Abstract]   [Full Text] [Related]  

  • 13. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
    Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
    Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
    Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
    Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
    Brandse JF; Peters CP; Gecse KB; Eshuis EJ; Jansen JM; Tuynman HA; Löwenberg M; Ponsioen CY; van den Brink GR; DʼHaens GR;
    Inflamm Bowel Dis; 2014 Feb; 20(2):251-8. PubMed ID: 24378599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local injection of adalimumab for perianal Crohn's disease: better than infliximab?
    Poggioli G; Laureti S; Pierangeli F; Bazzi P; Coscia M; Gentilini L; Gionchetti P; Rizzello F
    Inflamm Bowel Dis; 2010 Oct; 16(10):1631. PubMed ID: 20848458
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease.
    Swoger JM; Levesque BG
    Aliment Pharmacol Ther; 2014 Oct; 40(7):854-5. PubMed ID: 25185733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.